Burden of Illness in Patients with Light Chain (AL) Amyloidosis: A Real World Study Using Optum Claims Database

Author(s)

D'Souza A1, Abonour R2, Zonder J3, Hoffman J4, Wong SW5, Liedtke M6, Dispenzieri A7, Cote S8, Nair S9, Potluri R10, Weiss BM11, Vermeulen J11, Lam A12, Mehra M11
1Froedtert & Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA, 2Indiana Cancer Pavilion, Indianapolis, IN, USA, 3Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA, 4Sylvester Comprehensive Cancer Center, Miami, FL, USA, 5University of California, San Francisco, CA, USA, 6Stanford University, Stanford, CA, USA, 7Mayo Clinic, Rochester, MN, USA, 8Janssen Global Services, Raritan, NJ, USA, 9Janssen Pharmaceutica NV, Beerse, Belgium, 10SmartAnalyst Inc., New York, NY, USA, 11Janssen Global Medical Affairs, Horsham, PA, USA, 12Janssen Global Services, LLC, Raritan, NJ, USA

OBJECTIVES: To assess economic burden associated with AL amyloidosis and its treatment in a real-world setting.

METHODS: Data were extracted from the Optum Clinformatics claims database. Eligible patients were age ≥18 years with a diagnosis of AL amyloidosis or a diagnosis of amyloidosis and treatment with ≥1 line of therapy (LOT) consisting of ≥1 treatments from a prespecified list. Patients were required to have data available and could not have prior cancer for 1 year prior to index diagnosis. Index diagnosis was required to be on or after January 2008. Costs incurred during a LOT and up to next LOT in terms of per-patient per-LOT (PPPL) and per-patient per-month (PPPM) were calculated, and costs were stratified by presence or absence of organ failure. Health resource utilization per LOT was also evaluated. All analyses were descriptive.

RESULTS: 624 patients were included in this retrospective analysis. Mean PPPL and PPPM costs for LOT1 were $111,386 and $19,594, respectively. From initiation of LOT1 to loss to follow-up, the mean cumulative cost was $209,576 and mean PPPM cost was $19,845. Costs were higher with subsequent LOTs. PPPM costs were higher in patients with organ failure at baseline than in those without and in those who developed organ failure during follow-up compared with those who did not. During LOT1, 50%, 53%, 99%, and 91% of patients had ≥1 hospitalization, ER visit, outpatient visit, and lab test, respectively. The mean number of hospitalizations per patients during LOT1 was 1.3 and the mean length of stay was 9.0 days. Additional data will be presented.

CONCLUSIONS: AL amyloidosis is associated with substantial costs, which increase in patients treated with >1 LOT and in those with organ failure. These results highlight the need for therapies that provide rapid and deep hematologic response, prolong progression-free survival and reduce organ deterioration.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)

Code

PRO21

Topic

Economic Evaluation

Disease

Drugs

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×